Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 22.63M 16.16M 14.03M 12.93M 12.11M 1.55B 23.11M 154M 59.71M 746M 60.67M 59.37M 2.59B P/E Ratio 2024
-5.24x
P/E Ratio 2025 -7.5x
Enterprise Value 22.4M 16M 13.88M 12.8M 11.99M 1.53B 22.87M 153M 59.1M 738M 60.06M 58.76M 2.57B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
91.6%
Yield 2024 *
-
Yield 2025 -
1 day-10.00%
1 week+5.88%
Current month+5.88%
1 month-10.00%
3 months-40.00%
6 months-47.06%
Current year-47.06%
1 week 0.08
Extreme 0.075
0.1
1 month 0.07
Extreme 0.07
0.1
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.36
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Date Insider Type Main position Quantity % Market Cap.
03-15Option 16,367 0.0092%
03-15Other 0 0%
03-08Option

Executive/Senior Manager

150,000 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
-10.00%+5.88%-52.63%+38.46% 16.25M
+2.16%+3.17%+43.57%+160.71% 1,013B
-0.07%+4.45%+53.50%+49.05% 574B
-0.08%-0.08%+17.37%+63.20% 397B
-0.37%+4.97%+21.24%+15.95% 324B
+0.85%+2.79%+24.89%+15.93% 280B
+2.10%+7.06%+24.57%+34.79% 273B
+4.84%+2.45%+21.33%+62.89% 182B
-0.19%+3.96%-45.64%-48.23% 194B
+3.61%-2.56%+15.16%+61.66% 151B
Average +0.40%+4.15%+12.34%+45.44% 338.87B
Weighted average by Cap. +1.27%+3.99%+29.41%+72.79%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34
Net income -1.71M -1.22M -1.06M -975K -914K -117M -1.74M -11.63M -4.5M -56.27M -4.58M -4.48M -196M -3.53M -2.52M -2.19M -2.02M -1.89M -242M -3.61M -24.07M -9.32M -116M -9.47M -9.27M -405M
Net Debt -113K -80.43K -69.79K -64.33K -60.28K -7.7M -115K -767K -297K -3.71M -302K -295K -12.91M -231K -165K -143K -132K -123K -15.76M -235K -1.57M -608K -7.6M -618K -605K -26.42M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-06-11 0.0900 $ -10.00% 13,500
26-06-10 0.1000 $ +11.11% 361,865
26-06-09 0.0900 $ 0.00% 28,158
26-06-08 0.0900 $ -5.26% 423,450
26-06-05 0.0950 $ +11.76% 213,166

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!